XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
OPERATING EXPENSES:        
Research and development $ 13,977 $ 12,197 $ 45,259 $ 30,434
General and administrative 11,559 9,571 32,953 24,464
Total operating expenses 25,536 21,768 78,212 54,898
LOSS FROM OPERATIONS: (25,536) (21,768) (78,212) (54,898)
OTHER INCOME, NET:        
Other income, net 3,206 0 3,580 2
Foreign exchange gains 1,096 3,364 4,387 2,171
Benefit from R&D tax credit 2,983 2,618 9,982 6,733
Total other income, net 7,285 5,982 17,949 8,906
Loss before income taxes (18,251) (15,786) (60,263) (45,992)
Income tax expense (120) (63) (316) (100)
Net loss (18,371) (15,849) (60,579) (46,092)
Other comprehensive loss:        
Foreign exchange translation adjustment (15,156) (8,401) (39,483) (6,768)
Comprehensive loss $ (33,527) $ (24,250) $ (100,062) $ (52,860)
Net loss per share - basic (in dollars per share) $ (0.43) $ (0.38) $ (1.43) $ (1.17)
Net loss per share - diluted (in dollars per share) $ (0.43) $ (0.38) $ (1.43) $ (1.17)
Weighted average ordinary shares outstanding - basic (in shares) 42,525,855 41,708,220 42,377,895 39,378,824
Weighted average ordinary shares outstanding - diluted (in shares) 42,525,855 41,708,220 42,377,895 39,378,824